Three Australian fund managers who delivered annualised double-digit returns over the past 10 years share their views on what ...

Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Signal Advisors Wealth LLC increased its stake in ResMed Inc. (NYSE:RMD – Free Report) by 6.1% in the 4th quarter, according ...

The stock's rise snapped a four-day losing streak.

Up 42% in a year, not including dividends, here’s why ResMed Inc (ASX: RMD) shares can keep charging ahead in 2025.

LAS VEGAS, Jan. 11, 2025 /PRNewswire/ -- CES ® 2025, the most powerful tech event in the world, welcomed over 141,000 ...

Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.